| 论文作者 |
Guo, JC; Li, N; Liu, QL; Hao, ZY; Zhu, GH; Wang, XG; Wang, HL; Pan, Q; Xu, BT; Han, Y; Zhang, GY; Lian, YN; Zhang, W; Gu, YQ; Lin, NH; Zeng, X; Jin, ZG; Lan, WH; Jiang, J; Gao, D; Dong, L; Yuan, HR; Liang, CZ; Qin, J |
| 摘要 |
Double-negative prostate cancer (DNPC), characterized by an androgen receptor (AR)-and neuroendocrinenull phenotype, frequently emerges following androgen deprivation therapy (ADT). However, our understanding of the origins and regulatory mechanisms of DNPC remains limited. Here, we discover that tumors with KMT2C mutation or loss are highly susceptible to transitioning into DNPC following ADT. We clarify that DNPC primarily stems from luminal cell transdifferentiation rather than basal cell transformation. Antiandrogen treatment induces KMT2C binding at enhancers of a subset of AR-regulated genes, preserving the adenocarcinoma lineage. KMT2C maintains ASPP2 expression via enhancer-promoter communication post-AR inhibition, while its inactivation reduces ASPP2, triggering Delta Np63-dependent transdifferentiation. This DNPC transition maintains fatty acid (FA) synthesis through Delta Np63-mediated SREBP1c transactivation, fueling DNPC growth via HRAS palmitoylation and MAPK signaling activation. These findings highlight KMT2C as an epigenetic checkpoint against DNPC development and suggest the therapeutic potential of targeting fatty acid synthesis. |
官方微信
